Anti Mycoplasma pneumoniae activities of new quinolones, including moxifloxacin, a new compound of new quinolones and clarithromycin.

概要

論文の詳細を見る
We tested 100 strains of Mycoplasma pneumoniae for susceptibility to moxifloxacin, a new quinolone compound, using sparfloxacin, levofloxacin, ciprofloxacin, and clarithromycin as references. Among the 100 strains of M. pneumoniae isolated from throat swabs of patients with respiratory infectious disease, 39 strains were isolated prior to 1986, 24 strains between 1986-1990, and 37 strains between 1991-1995. The susceptibility of these strains to the above antimicrobial agents was determined by minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Of the new quinolones, moxifloxacin was the most active against these organisms, with MIC50 of the drug 0.08μg/mL and MBC60 0.08μg/mL. The MIC, os of sparfloxacin, levofloxacin, and ciprofloxacin were 0.15μg/mL, 0.6μmL, and 2.5μg/mL. The MBC50s of these drugs were 0.3μg/mL, 1.25μg/mL, and 2.5μg/mL. The MIC50 of clarithromycin was 0.008μg/mL, and the MBC60 was 0.015μg/mL. These results indicate that moxifloxacin possesses a high potentiality of anti-M. pneumoniae activity and is a promising antibiotic in thetreatment of mycoplasmal infections.
公益社団法人日本化学療法学会の論文